Published in Histochem Cell Biol on August 21, 2004
Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol (2008) 11.02
Resolution of inflammation: state of the art, definitions and terms. FASEB J (2007) 5.12
Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus. Br J Pharmacol (2007) 2.67
Apoptotic neutrophils and T cells sequester chemokines during immune response resolution through modulation of CCR5 expression. Nat Immunol (2006) 2.37
Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not? Am J Pathol (2010) 2.16
Identification and signature profiles for pro-resolving and inflammatory lipid mediators in human tissue. Am J Physiol Cell Physiol (2014) 1.99
Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. Circ Res (2010) 1.89
Saturated-efferocytosis generates pro-resolving CD11b low macrophages: modulation by resolvins and glucocorticoids. Eur J Immunol (2010) 1.70
Emerging roles of resolvins in the resolution of inflammation and pain. Trends Neurosci (2011) 1.60
The resolution of inflammation. Nat Rev Immunol (2012) 1.58
Chronic inflammation: a failure of resolution? Int J Exp Pathol (2007) 1.54
Resolution phase lipid mediators of inflammation: agonists of resolution. Curr Opin Pharmacol (2013) 1.50
Resolvins, specialized proresolving lipid mediators, and their potential roles in metabolic diseases. Cell Metab (2013) 1.45
Essential role for hematopoietic prostaglandin D2 synthase in the control of delayed type hypersensitivity. Proc Natl Acad Sci U S A (2006) 1.43
Resolvin D1 and resolvin D2 govern local inflammatory tone in obese fat. J Immunol (2012) 1.31
Inflammatory and immune pathways in the pathogenesis of periodontal disease. Periodontol 2000 (2014) 1.20
Protectins and maresins: New pro-resolving families of mediators in acute inflammation and resolution bioactive metabolome. Biochim Biophys Acta (2014) 1.14
Novel n-3 immunoresolvents: structures and actions. Sci Rep (2013) 1.10
Self-limited versus delayed resolution of acute inflammation: temporal regulation of pro-resolving mediators and microRNA. Sci Rep (2012) 1.09
Oral inflammatory diseases and systemic inflammation: role of the macrophage. Front Immunol (2012) 1.07
Pro-Resolving Lipid Mediators (SPMs) and Their Actions in Regulating miRNA in Novel Resolution Circuits in Inflammation. Front Immunol (2012) 1.06
Lipid mediators in the resolution of inflammation. Cold Spring Harb Perspect Biol (2014) 1.04
Phagocytic activity in human immunodeficiency virus type 1 infection. Clin Diagn Lab Immunol (2005) 1.01
Distinguishing health benefits of eicosapentaenoic and docosahexaenoic acids. Mar Drugs (2012) 0.99
Natural resolution of inflammation. Periodontol 2000 (2013) 0.97
Association of fatty acids in serum phospholipids with lung function and bronchial hyperresponsiveness in adults. Eur J Epidemiol (2008) 0.97
Apoptotic mimicry: phosphatidylserine liposomes reduce inflammation through activation of peroxisome proliferator-activated receptors (PPARs) in vivo. Br J Pharmacol (2007) 0.97
Paradigm shift in the pharmacological management of periodontal diseases. Front Oral Biol (2011) 0.94
A role for lipoxin A₄ as an anti-inflammatory mediator in the human endometrium. Reproduction (2011) 0.86
Cardiac physiology and clinical efficacy of dietary fish oil clarified through cellular mechanisms of omega-3 polyunsaturated fatty acids. Eur J Appl Physiol (2014) 0.84
Resolution of inflammation in periodontitis. J Periodontol (2005) 0.83
Catalytic characterization and cytokine mediated regulation of cytochrome P450 4Fs in rat hepatocytes. Arch Biochem Biophys (2007) 0.83
Host modulation therapy: An indispensable part of perioceutics. J Indian Soc Periodontol (2014) 0.81
Acute alcohol intake impairs lung inflammation by changing pro- and anti-inflammatory mediator balance. Alcohol (2007) 0.80
Effect of fish or soybean oil-rich diets on bradykinin, kallikrein, nitric oxide, leptin, corticosterone and macrophages in carrageenan stimulated rats. Inflammation (2005) 0.80
Testosterone regulates bone response to inflammation. Horm Metab Res (2014) 0.78
Maresin 1 induces a novel pro-resolving phenotype in human platelets. J Thromb Haemost (2017) 0.77
Discovery of specialized pro-resolving mediators marks the dawn of resolution physiology and pharmacology. Mol Aspects Med (2017) 0.77
A Novel Interaction between FLICE-Associated Huge Protein (FLASH) and E2A Regulates Cell Proliferation and Cellular Senescence via Tumor Necrosis Factor (TNF)-Alpha-p21WAF1/CIP1 Axis. PLoS One (2015) 0.75
Conditional Deletion of Smad1 Ameliorates Glomerular Injury in Progressive Glomerulonephritis. Sci Rep (2016) 0.75
Omega fatty acids and resolution of inflammation: A new twist in an old tale. J Indian Soc Periodontol (2010) 0.75
The histochemistry and cell biology vade mecum: a review of 2005-2006. Histochem Cell Biol (2006) 0.75
Recent progress in histochemistry. Histochem Cell Biol (2007) 0.75
Recent progress in histochemistry and cell biology: the state of the art 2005. Histochem Cell Biol (2005) 0.75
News and views in Histochemistry and Cell Biology. Histochem Cell Biol (2004) 0.75
Points of control in inflammation. Nature (2002) 10.61
Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science (1987) 8.36
Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med (2002) 7.99
Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells. Nature (2003) 7.56
Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med (1999) 6.91
Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol (2001) 5.87
The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet (2004) 5.31
C-reactive protein and the risk of incident colorectal cancer. JAMA (2004) 4.94
Role of prostacyclin in the cardiovascular response to thromboxane A2. Science (2002) 4.59
Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. J Biol Chem (2003) 4.58
Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc Natl Acad Sci U S A (2004) 4.28
Association of cystic fibrosis with abnormalities in fatty acid metabolism. N Engl J Med (2004) 4.09
Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J Biol Chem (2003) 3.80
Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci U S A (1995) 3.72
Transgenic mice: fat-1 mice convert n-6 to n-3 fatty acids. Nature (2004) 3.65
Mechanisms of action of docosahexaenoic acid in the nervous system. Lipids (2001) 3.49
Release of inflammatory mediators from stimulated neutrophils. N Engl J Med (1980) 3.35
On the specificity of the oxygenation of unsaturated fatty acids catalyzed by soybean lipoxidase. J Biol Chem (1967) 3.30
Anti-inflammatory lipid mediators and insights into the resolution of inflammation. Nat Rev Immunol (2002) 3.23
Cutting edge: lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages. J Immunol (2000) 3.07
Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A(4). Nat Med (2002) 2.94
Design of lipoxin A4 stable analogs that block transmigration and adhesion of human neutrophils. Biochemistry (1995) 2.75
Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor. Nat Med (2002) 2.75
Aspirin-triggered 15-epi-lipoxin A4 (LXA4) and LXA4 stable analogues are potent inhibitors of acute inflammation: evidence for anti-inflammatory receptors. J Exp Med (1997) 2.61
Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med (1999) 2.53
Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes. Proc Natl Acad Sci U S A (1984) 2.46
Identification of a human cDNA encoding a functional high affinity lipoxin A4 receptor. J Exp Med (1994) 2.38
Reduced inflammation and tissue damage in transgenic rabbits overexpressing 15-lipoxygenase and endogenous anti-inflammatory lipid mediators. J Immunol (2003) 2.23
Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo. Proc Natl Acad Sci U S A (1999) 2.21
Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med (2003) 2.18
The development of COX2 inhibitors. Nat Rev Drug Discov (2003) 2.14
Resolution of inflammation: a new paradigm for the pathogenesis of periodontal diseases. J Dent Res (2003) 2.12
Lipid mediator-induced expression of bactericidal/ permeability-increasing protein (BPI) in human mucosal epithelia. Proc Natl Acad Sci U S A (2002) 2.01
Lipoxin biosynthesis and its impact in inflammatory and vascular events. Biochim Biophys Acta (1994) 1.98
Lipoxin-mediated inhibition of IL-12 production by DCs: a mechanism for regulation of microbial immunity. Nat Immunol (2001) 1.97
Lipoxin a4 analogs attenuate induction of intestinal epithelial proinflammatory gene expression and reduce the severity of dextran sodium sulfate-induced colitis. J Immunol (2002) 1.95
Lipoxin A4 and B4 are potent stimuli for human monocyte migration and adhesion: selective inactivation by dehydrogenation and reduction. J Exp Med (1996) 1.92
Serum amyloid A induces IL-8 secretion through a G protein-coupled receptor, FPRL1/LXA4R. Blood (2002) 1.92
Parasite-induced lipoxin A4 is an endogenous regulator of IL-12 production and immunopathology in Toxoplasma gondii infection. J Exp Med (2002) 1.87
Neutrophil-mediated changes in vascular permeability are inhibited by topical application of aspirin-triggered 15-epi-lipoxin A4 and novel lipoxin B4 stable analogues. J Clin Invest (1998) 1.83
Lipoxins and novel aspirin-triggered 15-epi-lipoxins (ATL): a jungle of cell-cell interactions or a therapeutic opportunity? Prostaglandins (1997) 1.74
Docosahexaenoic acid is a strong inhibitor of prostaglandin but not leukotriene biosynthesis. Proc Natl Acad Sci U S A (1983) 1.67
Aspirin-triggered 15-epi-lipoxin A4 (ATL) generation by human leukocytes and murine peritonitis exudates: development of a specific 15-epi-LXA4 ELISA. J Pharmacol Exp Ther (1998) 1.66
Lipoxin A4 stable analogs are potent mimetics that stimulate human monocytes and THP-1 cells via a G-protein-linked lipoxin A4 receptor. J Biol Chem (1997) 1.66
Effects of exogenous arachidonic, eicosapentaenoic, and docosahexaenoic acids on the generation of 5-lipoxygenase pathway products by ionophore-activated human neutrophils. J Clin Invest (1984) 1.65
Leukotriene B4 receptor transgenic mice reveal novel protective roles for lipoxins and aspirin-triggered lipoxins in reperfusion. J Clin Invest (1999) 1.64
Leukocyte antiadhesive actions of annexin 1: ALXR- and FPR-related anti-inflammatory mechanisms. Blood (2003) 1.60
Workshop on the Essentiality of and Recommended Dietary Intakes for Omega-6 and Omega-3 Fatty Acids. J Am Coll Nutr (1999) 1.59
Identification of a human enterocyte lipoxin A4 receptor that is regulated by interleukin (IL)-13 and interferon gamma and inhibits tumor necrosis factor alpha-induced IL-8 release. J Exp Med (1998) 1.58
Lipoxins, aspirin-triggered epi-lipoxins, lipoxin stable analogues, and the resolution of inflammation: stimulation of macrophage phagocytosis of apoptotic neutrophils in vivo. J Am Soc Nephrol (2002) 1.57
Diets could prevent many diseases. Lipids (2003) 1.54
Lipoxin formation during human neutrophil-platelet interactions. Evidence for the transformation of leukotriene A4 by platelet 12-lipoxygenase in vitro. J Clin Invest (1990) 1.50
Unorthodox routes to prostanoid formation: new twists in cyclooxygenase-initiated pathways. J Clin Invest (2001) 1.49
Differential effects of aspirin and misoprostol on 15-hydroxyeicosatetraenoic acid generation by leukocytes from aspirin-sensitive asthmatic patients. J Allergy Clin Immunol (2003) 1.48
Aspirin, but not NO-releasing aspirin (NCX-4016), interacts with selective COX-2 inhibitors to aggravate gastric damage and inflammation. Am J Physiol Gastrointest Liver Physiol (2004) 1.47
A novel role for phospholipase A2 isoforms in the checkpoint control of acute inflammation. FASEB J (2004) 1.47
Angioplasty triggers intracoronary leukotrienes and lipoxin A4. Impact of aspirin therapy. Circulation (1992) 1.45
Lipoxins: revelations on resolution. Trends Pharmacol Sci (2001) 1.39
Lipoxin A(4) analogues inhibit leukocyte recruitment to Porphyromonas gingivalis: a role for cyclooxygenase-2 and lipoxins in periodontal disease. Biochemistry (2000) 1.38
Oxidoreductases in lipoxin A4 metabolic inactivation: a novel role for 15-onoprostaglandin 13-reductase/leukotriene B4 12-hydroxydehydrogenase in inflammation. J Biol Chem (2000) 1.35
Lipoxin recognition sites. Specific binding of labeled lipoxin A4 with human neutrophils. J Biol Chem (1992) 1.35
The opportunistic pathogen Pseudomonas aeruginosa carries a secretable arachidonate 15-lipoxygenase. Proc Natl Acad Sci U S A (2004) 1.33
Cyclooxygenase-2-derived lipoxin A4 increases gastric resistance to aspirin-induced damage. Gastroenterology (2002) 1.33
Cyclooxygenase-2-derived prostaglandin E2 and lipoxin A4 accelerate resolution of allergic edema in Angiostrongylus costaricensis-infected rats: relationship with concurrent eosinophilia. J Immunol (2000) 1.33
Transfection of rat kidney with human 15-lipoxygenase suppresses inflammation and preserves function in experimental glomerulonephritis. Proc Natl Acad Sci U S A (1999) 1.32
Lipoxin A4 metabolism by differentiated HL-60 cells and human monocytes: conversion to novel 15-oxo and dihydro products. Biochemistry (1993) 1.30
Aspirin-tolerant asthmatics generate more lipoxins than aspirin-intolerant asthmatics. Eur Respir J (2000) 1.29
Human ALX receptor regulates neutrophil recruitment in transgenic mice: roles in inflammation and host defense. FASEB J (2003) 1.29
Novel lipid mediator regulators of endothelial cell proliferation and migration: aspirin-triggered-15R-lipoxin A(4) and lipoxin A(4). J Pharmacol Exp Ther (2002) 1.27
Cutting edge: lipoxin (LX) A4 and aspirin-triggered 15-epi-LXA4 block allergen-induced eosinophil trafficking. J Immunol (2000) 1.26
Exogenous pathogen and plant 15-lipoxygenase initiate endogenous lipoxin A4 biosynthesis. J Exp Med (2004) 1.24
Modification of the transcriptomic response to renal ischemia/reperfusion injury by lipoxin analog. Kidney Int (2003) 1.21
Lipoxins are potential endogenous antiinflammatory mediators in asthma. Am J Respir Crit Care Med (2002) 1.16
Activation of the fatty acid alpha-dioxygenase pathway during bacterial infection of tobacco leaves. Formation of oxylipins protecting against cell death. J Biol Chem (2003) 1.12
Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosa. Proc Natl Acad Sci U S A (2003) 1.11
Biomedicine. Back to an aspirin a day? Science (2002) 1.11
Pilot study of dietary fatty acid supplementation in the treatment of adult periodontitis. Prostaglandins Leukot Essent Fatty Acids (2003) 1.09
Formation of novel D-ring and E-ring isoprostane-like compounds (D4/E4-neuroprostanes) in vivo from docosahexaenoic acid. Biochemistry (2000) 1.09
Relative contribution of acetylated cyclo-oxygenase (COX)-2 and 5-lipooxygenase (LOX) in regulating gastric mucosal integrity and adaptation to aspirin. FASEB J (2003) 1.09
15-Epi-16-(para-fluorophenoxy)-lipoxin A(4)-methyl ester, a synthetic analogue of 15-epi-lipoxin A(4), is protective in experimental ischemic acute renal failure. J Am Soc Nephrol (2002) 1.08
Glucocorticoid-mediated regulation of granulocyte apoptosis and macrophage phagocytosis of apoptotic cells: implications for the resolution of inflammation. J Endocrinol (2003) 1.07
Lipoxins induce actin reorganization in monocytes and macrophages but not in neutrophils: differential involvement of rho GTPases. Am J Pathol (2002) 1.05
Changes in phosphatidylinositol and phosphatidic acid in stimulated human neutrophils. Relationship to calcium mobilization, aggregation and superoxide radical generation. Biochim Biophys Acta (1983) 1.05
Lipoxins in chronic inflammation. Crit Rev Oral Biol Med (2003) 1.02
Oxidation of docosahexaenoic acid by rat liver microsomes. J Biol Chem (1984) 1.01
An aspirin-triggered lipoxin A4 stable analog displays a unique topical anti-inflammatory profile. J Immunol (2002) 1.01
Lipoxin A4 antagonizes the mitogenic effects of leukotriene D4 in human renal mesangial cells. Differential activation of MAP kinases through distinct receptors. J Biol Chem (2000) 1.01
A novel rat lipoxin A4 receptor that is conserved in structure and function. Br J Pharmacol (2003) 1.00
Aspirin-triggered lipoxin A4 and lipoxin A4 up-regulate transcriptional corepressor NAB1 in human neutrophils. FASEB J (2001) 0.98
Hepatocytes are a rich source of novel aspirin-triggered 15-epi-lipoxin A(4). Am J Physiol (1999) 0.98
Lipoxin, leukotriene, and PDGF receptors cross-talk to regulate mesangial cell proliferation. FASEB J (2002) 0.98
Lipoxin A4 stimulates a cytosolic Ca2+ increase in human bronchial epithelium. J Biol Chem (2002) 0.98
A magic bullet for mucosal protection...and aspirin is the trigger! Trends Pharmacol Sci (2003) 0.97
Expression of BPI (bactericidal/permeability-increasing protein) in human mucosal epithelia. Biochem Soc Trans (2003) 0.96
Lipoxygenation of docosahexaenoic acid by the rat pineal body. J Neurochem (1994) 0.95